Centers for Disease Control and Prevention. Opioid Overdose: Understanding the Epidemic. https://www.cdc.gov/drugoverdose/epidemic/index.html. Published 2018. Accessed Jun, 2019.
Guy G, Zhang K, Bohm M, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. Morbid Mortal Wkly Rep 2017;66(26):697-704.
Oregon Pain Guidance. Tapering - guidance and tools. https://www.oregonpainguidance.org/guideline/tapering/. Published 2018. Accessed Aug, 2019.
American Academy of Family Physicians. Tapering Resource. https://www.aafp.org/dam/AAFP/documents/patient_care/pain_management/tapering-resource.pdf. Accessed Aug, 2019.
Washington State Agency Medical Directors' Group. Interagency guideline on prescribing opioids for pain. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf. Published 2015. Accessed Aug, 2019.
Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf. Published 2017. Accessed.
Bohnert A, Logan J, Ganoczy D, Dowell D. A detailed exploration into the association of prescribed opioid dosage and overdose deathes among patients with chornic pain. Med Care 2016;54(5):435-441.
Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med 2017;167(3):181-191.
Throckmorton D. Statement by Douglas Throckmorton, MD, Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on new Opioid Analgesic Labeling Changes. https://www.fda.gov/news-events/press-announcements/statement-douglas-throckmorton-md-deputy-center-director-regulatory-programs-fdas-center-drug-0. Published 2019. Accessed Jul, 2019.
Dowell D, Haegerich T, Chou R. No Shortcuts to Safer Opioid Prescribing. N Engl J Med 2019.
Mackey K, Anderson J, Bourne D, Chen E, Peterson K. Evidence Brief: Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs VA ESP Project #09-199. 2019. https://www.hsrd.research.va.gov/publications/esp/reports.cfm.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research Ed). 2009;339:b2535.
Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. In. Rockville, MD: Agency for Healthcare Research and Quality; January 2014:Chapters available at: www.effectivehealthcare.ahrq.gov.
Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.
Grading of Recommendations Assessment Development and Evaluation. Grade Working Group. https://www.gradeworkinggroup.org/. Published 2019. Accessed Jan, 2020.
Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A clinical trial comparing tapering doses of buprenorphine with steady doses for chronic pain and co-existent opioid addiction. J Addict Med 2010;4(3):140-146.
Cowan DT, Wilson-Barnett J, Griffiths P, Vaughan DJ, Gondhia A, Allan LG. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med 2005;6(2):113-121.
Sullivan MD, Turner JA, DiLodovico C, D'Appollonio A, Stephens K, Chan Y-F. Prescription opioid taper support for outpatients with chronic pain: A randomized controlled trial. J Pain 2017;18(3):308-318.
Webster L, Harper J, Stambler N, Israel R. Analysis of impact of oral methylnaltrexone for opioid-induced constipation (OIC) on opioid analgesia and withdrawal symptoms in patients with chronic noncancer pain (CNCP) taking methadone. Pain Med (United States). 2017;18 (3):620.
Schwarzer A, Aichinger-Hinterhofer M, Maier C, Vollert J, Walther JW. Sleep-disordered breathing decreases after opioid withdrawal: results of a prospective controlled trial. Pain. 2015;156(11):2167-2174.
Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag 2006;2(5):277-282.
Berland DW, Malinoff HL, Weiner MA, Przybylski R. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization. Am J Ther 2013;20(4):316-321.
Crisostomo RA, Schmidt JE, Hooten WM, Kerkvliet JL, Townsend CO, Bruce BK. Withdrawal of analgesic medication for chronic low-back pain patients: improvement in outcomes of multidisciplinary rehabilitation regardless of surgical history. Am J Phys Med Rehabil 2008;87(7):527-536.
Cunningham JL, Evans MM, King SM, Gehin JM, Loukianova LL. Opioid tapering in fibromyalgia patients: experience from an interdisciplinary pain rehabilitation program. Pain Med 2016;17(9):1676-1685.
Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J, Jr. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med 2014;15(12):2087-2094.
Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J, Jr. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012;15(3 Suppl):Es59-66.
Darchuk KM, Townsend CO, Rome JD, Bruce BK, Hooten WM. Longitudinal treatment outcomes for geriatric patients with chronic non-cancer pain at an interdisciplinary pain rehabilitation program. Pain Med 2010;11(9):1352-1364.
Dersh J, Mayer TG, Gatchel RJ, Polatin PB, Theodore BR, Mayer EA. Prescription opioid dependence is associated with poorer outcomes in disabling spinal disorders. Spine. 2008;33(20):2219-2227.
Drossman DA, Morris CB, Edwards H, et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am J Gastroenterol 2012;107(9):1426-1440.
Harden P, Ahmed S, Ang K, Wiedemer N. Clinical implications of tapering chronic opioids in a veteran population. Pain Med 2015;16(10):1975-1981.
Heiwe S, Lonnquist I, Kallmen H. Potential risk factors associated with risk for drop-out and relapse during and following withdrawal of opioid prescription medication. Eur J Pain 2011;15(9):966-970.
Hooten WM, Townsend CO, Bruce BK, Warner DO. The effects of smoking status on opioid tapering among patients with chronic pain. Anesth Analg 2009;108(1):308-315.
Hooten WM, Townsend CO, Sletten CD, Bruce BK, Rome JD. Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Med 2007;8(1):8-16.
Hooten WM, Townsend CO, Decker PA. Gender differences among patients with fibromyalgia undergoing multidisciplinary pain rehabilitation. Pain Med 2007;8(8):624-632.
Hooten WM, Warner DO. Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial. Addict Behav 2015;42:69-72.
Huffman KL, Rush TE, Fan Y, et al. Sustained improvements in pain, mood, function and opioid use post interdisciplinary pain rehabilitation in patients weaned from high and low dose chronic opioid therapy. Pain. 2017;158(7):1380-1394.
Kidner CL, Mayer TG, Gatchel RJ. Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders. J Bone Joint Surg 2009;91(4):919-927.
Krumova EK, Bennemann P, Kindler D, Schwarzer A, Zenz M, Maier C. Low pain intensity after opioid withdrawal as a first step of a comprehensive pain rehabilitation program predicts long-term nonuse of opioids in chronic noncancer pain. Clin J Pain 2013;29(9):760-769.
Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005;12(5):379-384.
Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain 2013;29(2):109-117.
Nilsen HK, Stiles TC, Landro NI, Fors EA, Kaasa S, Borchgrevink PC. Patients with problematic opioid use can be weaned from codeine without pain escalation. Acta Anaesthesiol Scand 2010;54(5):571-579.
Rome JD, Townsend CO, Bruce BK, Sletten CD, Luedtke CA, Hodgson JE. Chronic noncancer pain rehabilitation with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. Mayo Clin Proc 2004;79(6):759-768.
Rosenblum A, Cruciani RA, Strain EC, et al. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag 2012;8(6):369-382.
Roux P, Sullivan MA, Cohen J, et al. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain. 2013;154(8):1442-1448.
Taylor CB, Zlutnick SI, Corley MJ, Flora J. The effects of detoxification, relaxation, and brief supportive therapy on chronic pain. Pain. 1980;8(3):319-329.
Townsend CO, Kerkvliet JL, Bruce BK, et al. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission. Pain. 2008;140(1):177-189.
Wang H, Akbar M, Weinsheimer N, Gantz S, Schiltenwolf M. Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain. Pain Med 2011;12(12):1720-1726.
Weimer MB, Hartung DM, Ahmed S, Nicolaidis C. A chronic opioid therapy dose reduction policy in primary care. Subst Abus 2016;37(1):141-147.
Younger J, Barelka P, Carroll I, et al. Reduced cold pain tolerance in chronic pain patients following opioid detoxification. Pain Med 2008;9(8):1158-1163.
Kurita GP, Hojsted J, Sjogren P. Tapering off long-term opioid therapy in chronic non-cancer pain patients: A randomized clinical trial. Eur J Pain 2018;22(8):1528-1543.
Bienek N, Maier C, Kaisler M, Michel-Lauter B, Schwarzer A, Meyer-Friesem CH. Intensity of withdrawal symptoms during opioid taper in patients with chronic pain-individualized or fixed starting dosage? Pain Med 2019;26.
Sharp AL, Shen E, Wu YL, et al. Satisfaction with care after reducing opioids for chronic pain. Am J Manag Care 2018;24(6):e196-e199.
Thakral M, Walker RL, Saunders K, et al. Impact of opioid dose reduction and risk mitigation initiatives on chronic opioid therapy patients at higher risk for opioid-related adverse outcomes. Pain Med 2018;19(12):2450-2458.
Von Korff M, Saunders K, Dublin S, et al. Impact of chronic opioid therapy risk reduction initiatives on opioid overdose. J Pain 2019;20(1):108-117.
Darnall BD, Ziadni MS, Stieg RL, Mackey IG, Kao MC, Flood P. Patient-centered prescription opioid tapering in community outpatients with chronic pain. JAMA Intern Med 2018;178(5):707-708.
Demidenko MI, Dobscha SK, Morasco BJ, Meath TH, Ilgen MA, Lovejoy TI. Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users. Gen Hosp Psychiatry 2017;47:29-35.
Hundley L, Spradley S, Donelenko S. Assessment of outcomes following high-dose opioid tapering in a Veterans Healthcare System. J Opioid Manag 2018;14(2):89-101.
McPherson S, Lederhos Smith C, Dobscha SK, et al. Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain. Pain. 2018;159(10):2097-2104.
Mark T, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abus Treat 2019.
DiBenedetto DJ, Wawrzyniak KM, Finkelman M, et al. Relationships Between Opioid Dosing, Pain Severity, and Disability in a Community-Based Chronic Pain Population: An Exploratory Retrospective Analysis. Pain Med 2019;17:17.
James JR, Scott JM, Klein JW, et al. Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study. J Gen Intern Med 2019;34(12):2749-2755.
Perez HR, Buonora M, Cunningham CO, Heo M, Starrels JL. Opioid Taper Is Associated with Subsequent Termination of Care: a Retrospective Cohort Study. J Gen Intern Med 2019;19:19.
Nicholas MK, Asghari A, Sharpe L, et al. Reducing the use of opioids by patients with chronic pain: an effectiveness study with long-term follow-up. Pain. 2019;19:19.
Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4(12):1721-1728.
Townsend MJ, Kelly L, Ogur B. A group program for chronic pain patients on chronic opioids. J Gen Intern Med 2018;33(2 Suppl 1):758-759.
Murphy GSJ. Methadone provides a preventive analgesic effect in patients undergoing cardiac surgery. Anaesth Intensive Care.47(2):6-7.
Kertesz SG. Outcomes after opioid dose reductions and stoppage: It's time to start counting. J Subst Abus Treat 2019;103:64-65.